Lyka Labs Ltd.

₹75.03

1.7 (2.3%)

LYKALABS Share Price

Pharmaceuticals & Biotechnology

As on January 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 268 Cr

P/E Ratio33.42

Dividend YieldN/A

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	74.06	Bullish
10-DMA	75.07	Bearish
20-DMA	77.02	Bearish
50-DMA	78.2	Bearish
100-DMA	87.18	Bearish
200-DMA	99.12	Bearish

Historical Performance

1 Year

-46.8%

3 Years

-42.8%

5 Years

166.1%

10 Years

-21.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	1,385	1,112	931	1,941	863
Total Expenditure	1,206	955	762	929	666
Other Income	22	15	34	21	16
Operating Profit	202	172	202	1,032	212
Interest	23	49	119	201	259
Depreciation	68	128	141	173	83
Profit Before Tax	111	-9	-132	592	-141
Consolidated Net Profit	80	-25	-132	390	-116
Adjusted EPS	2	-1	-4	14	-4

Compounded Sales Growth

10 Years:1.2

5 Years:17.6

3 Years:-6.5

TTM:4.5

Compounded Profit Growth

10 Years:16.8

5 Years:-46

3 Years:-27.1

TTM:2.2

Stock Price CAGR

10 Years:-2.3

5 Years:20.4

3 Years:-17

TTM:-49.7

Return on Equity

10 Years:1.7

5 Years:-4

3 Years:-4.3

last year:2.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	357	331	307	287	287
Total Reserves	679	260	-27	-154	-545
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	260	508	733	728	1,489
Other Current Liabilities	153	124	143	662	231
Short Term Borrowings	148	116	76	201	104
Total Liabilities	1,762	1,569	1,515	1,856	1,737
Capital Work in Progress	2	220	151	162	162
Long Term Loans & Advances	224	254	230	217	206
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	41	48	25	56	42
Total Current Assets	674	507	442	522	291
Total Assets	1,762	1,569	1,515	1,856	1,737
Adjusted Book Value	29	18	9	5	-9

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 33.42, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -17.1%, indicating poor shareholder returns.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹202 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹1385 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 503726.1

No. of Shares: 6714 (Approx)

Performance:-49.6%

P/L: ₹-496273.9

NIFTY Performance: 9.4%

1 day Top Gainers